BioCentury | Sep 1, 2003
Strategy

Cengent: Adding at the ends

Lesson: While private companies can use M&A to construct more complete business systems, it’s also never too early to begin rationalizing the balance sheet. It took Structural Bioinformatics Inc. and GeneFormatics Inc. three tries to...
BC Week In Review | May 26, 2003
Company News

GeneFormatics, Structural Bioinformatics deal

The companies completed their previously announced merger to form a proteomics-based discovery company (see BioCentury, Jan. 13). The combined company will be called Cengent Therapeutics. GeneFormatics Inc. , San Diego, Calif.   Structural Bioinformatics Inc. , San...
BC Week In Review | Jan 20, 2003
Company News

ProSanos Corp. management update

ProSanos Corp. , La Jolla, Calif.   Business: Bioinformatics   Hired: Vincent Gotz as SVP of business solutions, formerly CBO of GeneFormatics  ...
BC Week In Review | Jan 13, 2003
Company News

GeneFormatics, Structural Bioinformatics deal

The companies will merge to form a proteomics-based discovery company. The deal combines Structural Bioinformatics’s Genes to Leads technology with GeneFormatics’s Diamond technologies that integrate structural and chemo-proteomics. The combined company will have Structural Bioinformatics’s...
BC Extra | Jan 6, 2003
Company News

Structural Bio, GeneFormatics merging

Structural Bioinformatics (San Diego, Calif.) and GeneFormatics (San Diego, Calif.) will merge to form a proteomics-based discovery company. The deal combines Structural Bioinformatics's Genes to Leads technology with GeneFormatics's Diamond technologies that integrate structural and...
BC Week In Review | Jul 29, 2002
Company News

De Novo Pharmaceuticals, GeneFormatics deal

The companies will research small molecule inhibitors of the M10 family of matrix metalloproteinases (MMPs). Under the deal, GeneFormatics will use its proteomics technologies to identify all members of the M10 family in the human...
BC Extra | Jul 22, 2002
Company News

De Novo, GeneFormatics MMP deal

De Novo (Cambridge, U.K.) and GeneFormatics (San Diego, Calif.) partnered to identify small molecule inhibitors of the M10 family of matrix metalloproteinases (MMPs). GeneFormatics will use its proteomics technologies to identify members of the M10...
BC Week In Review | Jul 15, 2002
Company News

Arakis, GeneFormatics deal

The companies partnered to develop performance enhanced medicines (PEMs). GeneFormatics will use its structural proteomics technology to identify and describe secondary biochemical functional sites of established drugs, and Arakis will use its database technologies to...
BC Extra | Jul 8, 2002
Company News

GeneFormatics, Arakis reprofiling deal

GeneFormatics (San Diego, Calif.) and Arakis (Little Chesterford, U.K.) partnered to develop performance enhanced medicines (PEMs). GeneFormatics will use its structural proteomics technology to identify and describe secondary biochemical functional sites of established drugs, and...
BC Week In Review | Apr 29, 2002
Company News

GeneFormatics, Incyte Genomics Inc. deal

GeneFormatics will use its Diamond proteomics technologies to identify and characterize full-length human protein sequences from INCY. INCY may then use resulting information to build its genomics IP. GeneFormatics Inc. , San Diego, Calif.   Incyte...
Items per page:
1 - 10 of 38
BioCentury | Sep 1, 2003
Strategy

Cengent: Adding at the ends

Lesson: While private companies can use M&A to construct more complete business systems, it’s also never too early to begin rationalizing the balance sheet. It took Structural Bioinformatics Inc. and GeneFormatics Inc. three tries to...
BC Week In Review | May 26, 2003
Company News

GeneFormatics, Structural Bioinformatics deal

The companies completed their previously announced merger to form a proteomics-based discovery company (see BioCentury, Jan. 13). The combined company will be called Cengent Therapeutics. GeneFormatics Inc. , San Diego, Calif.   Structural Bioinformatics Inc. , San...
BC Week In Review | Jan 20, 2003
Company News

ProSanos Corp. management update

ProSanos Corp. , La Jolla, Calif.   Business: Bioinformatics   Hired: Vincent Gotz as SVP of business solutions, formerly CBO of GeneFormatics  ...
BC Week In Review | Jan 13, 2003
Company News

GeneFormatics, Structural Bioinformatics deal

The companies will merge to form a proteomics-based discovery company. The deal combines Structural Bioinformatics’s Genes to Leads technology with GeneFormatics’s Diamond technologies that integrate structural and chemo-proteomics. The combined company will have Structural Bioinformatics’s...
BC Extra | Jan 6, 2003
Company News

Structural Bio, GeneFormatics merging

Structural Bioinformatics (San Diego, Calif.) and GeneFormatics (San Diego, Calif.) will merge to form a proteomics-based discovery company. The deal combines Structural Bioinformatics's Genes to Leads technology with GeneFormatics's Diamond technologies that integrate structural and...
BC Week In Review | Jul 29, 2002
Company News

De Novo Pharmaceuticals, GeneFormatics deal

The companies will research small molecule inhibitors of the M10 family of matrix metalloproteinases (MMPs). Under the deal, GeneFormatics will use its proteomics technologies to identify all members of the M10 family in the human...
BC Extra | Jul 22, 2002
Company News

De Novo, GeneFormatics MMP deal

De Novo (Cambridge, U.K.) and GeneFormatics (San Diego, Calif.) partnered to identify small molecule inhibitors of the M10 family of matrix metalloproteinases (MMPs). GeneFormatics will use its proteomics technologies to identify members of the M10...
BC Week In Review | Jul 15, 2002
Company News

Arakis, GeneFormatics deal

The companies partnered to develop performance enhanced medicines (PEMs). GeneFormatics will use its structural proteomics technology to identify and describe secondary biochemical functional sites of established drugs, and Arakis will use its database technologies to...
BC Extra | Jul 8, 2002
Company News

GeneFormatics, Arakis reprofiling deal

GeneFormatics (San Diego, Calif.) and Arakis (Little Chesterford, U.K.) partnered to develop performance enhanced medicines (PEMs). GeneFormatics will use its structural proteomics technology to identify and describe secondary biochemical functional sites of established drugs, and...
BC Week In Review | Apr 29, 2002
Company News

GeneFormatics, Incyte Genomics Inc. deal

GeneFormatics will use its Diamond proteomics technologies to identify and characterize full-length human protein sequences from INCY. INCY may then use resulting information to build its genomics IP. GeneFormatics Inc. , San Diego, Calif.   Incyte...
Items per page:
1 - 10 of 38